Atlas Trials

Ningetinib (CT053PTSA) Plus Gefitinib in Stage IIIB or IV NSCLC Patients With EGFR Mutation and T790M Negative

Clinical trial NCT03758287 · COMPLETED

Trial details

NCT number
NCT03758287
Sponsor
Sunshine Lake Pharma Co., Ltd.
Status
COMPLETED
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Non-small Cell Lung Cancer
Start date
2016-11-01
Primary completion
2021-09-17
Enrollment
108

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.